A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1428 participants.
Also called NCT04537923
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,428 participants
- Sponsor
- Registry
-
NCT04537923 -
2020-000284-23
-
- Other papers using this trial's data
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Belgium, Brazil, Czechia, Germany, Greece, Hungary, Italy, Mexico, Puerto Rico, Romania, Russia, Slovakia, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT04537923. Randomized; no masking; primary purpose treatment. Start 2020-10-19 (actual); primary completion 2022-10-11 (actual). Results posted on 2023-11-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
- Acronym
- SURPASS-6
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Insulin Lispro (U100)
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04537923- Content hash
6f131ee5e5bcf03b8191df078bc76238e1de687a4c11697f561ffd3b7da07898